rHEALTH Technology Granted US Patent for Small Volume Blood Handling in Point-of-Care Devices
BEDFORD, Mass., January 5, 2020 — rHEALTH LLC and its affiliate DNA Medicine Institute, Inc. announced today the issuance of United States Patent No. 10,449,537, titled “Capillary manipulation of clinical samples.”
This patent introduces a breakthrough system for the collection and delivery of minute blood samples, dramatically simplifying point-of-care diagnostics. Handling tiny blood volumes—commonly obtained via fingerstick—has long been a bottleneck in decentralized testing. Patent 10,449,537 enables reliable processing of these samples to deliver accurate clinical results outside traditional laboratory settings, including homes, clinics, and other non-traditional environments.
“This patent represents a seminal milestone in our portfolio,” said Dr. Eugene Y. Chan, CEO. “The linchpin of accurate blood analysis is precise collection, sampling, and manipulation of minute blood volumes, and this patent defines exactly how that is accomplished.”
The rHEALTH technology uses a single drop of blood (<20 µL) to provide results in just 15 minutes through an app-driven, Bluetooth-connected interface. Backed by NASA for monitoring astronaut health during long-duration space missions, the platform is engineered to bring accurate, comprehensive diagnostics to locations where conventional testing is unavailable.
With this issuance, the rHEALTH portfolio now includes a dozen issued patents covering sample handling, small-volume blood analysis, massive assay multiplexing, and device design. Together, these patents confer exclusive rights to rHEALTH’s approach to small-volume blood diagnostics for 20 years from the original filing date.
About rHEALTH®
rHEALTH is focused on developing and commercializing Diagnose Yourself, Anywhere™ technology. Its innovations include:
rHEALTH Diagnostic Platform – enables multiple laboratory test classes from a single small-volume blood sample at the point-of-care.
SKYE Sensor – a wireless wearable providing comprehensive, real-time vitals monitoring.
CHAS – a user-friendly mobile application for test management and results.
For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator advancing patient care and treating disease through innovation. Supported by NASA, NIH, and the Bill & Melinda Gates Foundation, DMI applies interdisciplinary science and engineering expertise to solve complex healthcare challenges.
For more information, visit www.dnamedinstitute.com.
Media Contact
Press Releases
Phone: (617) 913-7630
Email: pr@rhealth.com